Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David R. Lichtenstein is active.

Publication


Featured researches published by David R. Lichtenstein.


Gastrointestinal Endoscopy | 2002

Risk factors for complications after performance of ERCP

Jo Vandervoort; Roy Soetikno; Tony Tham; Richard C.K. Wong; Angelo Paulo Ferrari; Henry Montes; Alfred Roston; A Slivka; David R. Lichtenstein; Frederick W. Ruymann; Jacques Van Dam; Michael Hughes; David L. Carr-Locke

BACKGROUNDnERCP has become widely available for the diagnosis and treatment of benign and malignant pancreaticobiliary diseases. In this prospective study, the overall complication rate and risk factors for diagnostic and therapeutic ERCP were identified.nnnMETHODSnData were collected prospectively on patient characteristics and endoscopic techniques from 1223 ERCPs performed at a single referral center and entered into a database. Univariate and multivariate analyses were used to identify risk factors for ERCP-associated complications.nnnRESULTSnOf 1223 ERCPs performed, 554 (45.3%) were diagnostic and 667 (54.7%) therapeutic. The overall complication rate was 11.2%. Post-ERCP pancreatitis was the most common (7.2%) and in 93% of cases was self-limiting, requiring only conservative treatment. Bleeding occurred in 10 patients (0.8%) and was related to a therapeutic procedure in all cases. Nine patients had cholangitis develop, most cases being secondary to incomplete drainage. There was one perforation (0.08%). All other complications totaled 1.5%. Variables derived from cannulation technique associated with an increased risk for post-ERCP pancreatitis were precut access papillotomy (20%), multiple cannulation attempts (14.9%), sphincterotome use to achieve cannulation (13.1%), pancreatic duct manipulation (13%), multiple pancreatic injections (12.3%), guidewire use to achieve cannulation (10.2%), and the extent of pancreatic duct opacification (10%). Patient characteristics associated with an increased risk of pancreatitis were sphincter of Oddi dysfunction (21.7%) documented by manometry, previous ERCP-related pancreatitis (19%), and recurrent pancreatitis (16.2%). Pain during the procedure was an important indicator of an increased risk of post-ERCP pancreatitis (27%). Independent risk factors for post-ERCP pancreatitis were identified as a history of recurrent pancreatitis, previous ERCP-related pancreatitis, multiple cannulation attempts, pancreatic brush cytology, and pain during the procedure.nnnCONCLUSIONSnThe most frequent ERCP-related complication was pancreatitis, which was mild in the majority of patients. The frequency of post-ERCP pancreatitis was similar for both diagnostic and therapeutic procedures. Bleeding was rare and mostly associated with sphincterotomy. Other complications such as cholangitis and perforation were rare. Specific patient- and technique-related characteristics that can increase the risk of post-ERCP complications were identified.


Gastrointestinal Endoscopy | 1999

Accuracy and complication rate of brush cytology from bile duct versus pancreatic duct

Jo Vandervoort; Roy Soetikno; Henry Montes; David R. Lichtenstein; Jacques Van Dam; Frederick W. Ruymann; Edmund S. Cibas; David L. Carr-Locke

BACKGROUNDnThe accuracy and complication rates of brush cytology obtained from pancreaticobiliary strictures have not been fully defined. In this study we compared the accuracy and complications of brush cytology obtained from bile versus pancreatic ducts.nnnMETHODSnWe identified 148 consecutive patients for whom brush cytology was done during an ERCP from a database with prospectively collected data. We compared cytology results with the final diagnosis as determined by surgical pathologic examination or long-term clinical follow-up. We followed all patients and recorded ERCP-related complications.nnnRESULTSnForty-two pancreatic brush cytology samples and 101 biliary brush cytology samples were obtained. The accuracy rate of biliary cytology was 65 of 101 (64.3%) and the accuracy rate of pancreatic cytology was 30 of 42 (71.4%). Overall sensitivity was 50% for biliary cytology and 58.3% for pancreatic cytology. Of 67 patients with pancreatic adenocarcinoma, sensitivity for biliary cytology was 50% versus 66% for pancreatic cytology. Concurrent pancreatic and biliary cytology during the same procedure increased the sensitivity in only 1 of 10 (10%) patients. Pancreatitis occurred in 11 (11%) patients (9 mild cases, 2 moderate cases) after biliary cytology and in 9 (21%) patients (6 mild cases, 3 moderate cases) after pancreatic cytology (p = 0.22). In 10 patients who had pancreatic brush cytology, a pancreatic stent was placed. None of these patients developed pancreatitis versus 9 of 32 (28%) patients in whom a stent was not placed (p = 0.08). Pancreatic cytology samples obtained from the head of the pancreas were correct in 13 of 18 (72%) cases, from the genu in 7 of 7 (100%) cases, from the body in 5 of 9 (55%) cases, and from the tail in 4 of 7 (57%) cases.nnnCONCLUSIONnThe accuracy of biliary brush cytology is similar to the accuracy of pancreatic brush cytology. The yield of the latter for pancreatic adenocarcinoma is similar to that of the former. Complication rates for pancreatic cytology are not significantly higher than the rates for biliary cytology. The placement of a pancreatic stent after pancreatic brushing appears to reduce the risk of postprocedure pancreatitis.


The American Journal of Gastroenterology | 2003

Safety of ERCP during pregnancy.

T.C.K Tham; Jo Vandervoort; Richard C.K. Wong; Henry Montes; A.D Roston; A Slivka; A.P Ferrari; David R. Lichtenstein; J Van Dam; R.D Nawfel; R Soetikno; David L. Carr-Locke

OBJECTIVES:There are few data in the literature regarding the indications, therapy, and safety of endoscopic management of pancreatico-biliary disorders during pregnancy. We report the largest single center experience with ERCP in pregnancy.METHODS:We reviewed 15 patients that underwent ERCP during pregnancy. In all patients, the pelvis was lead-shielded and the fetus was monitored by an obstetrician. Fluoroscopy was minimized and hard copy radiographs taken only when essential.RESULTS:The mean patient age was 28.9 yr (15–36 yr). The mean duration of gestation was 25 wk (12–33 wk); one patient was in the first, five in the second, and nine in the third trimester. The indications were gallstone pancreatitis (n = 6), choledocholithiasis on ultrasound (n = 5), elevated liver enzymes and a dilated bile duct on ultrasound (n = 2), abdominal pain and gallstones (n = 1), and chronic pancreatitis (n = 1). ERCP findings were bile duct stones (n = 6), patulous papilla (n = 1), bile duct debris (n = 1), normal bile duct and gallstones or gallbladder sludge (n = 3), dilated bile duct and gallstones (n = 1), normal bile duct and no gallstones (n = 2), and chronic pancreatitis (n = 1). Six patients underwent sphincterotomies and one a biliary stent insertion. One sphincterotomy was complicated by mild pancreatitis. All infants delivered to date have had Apgar-scores >8, and continuing pregnancies are uneventful. Mean fluorosocopy time was 3.2 min (SD ± 1.8). An estimated fetal radiation exposure was 310 mrad (SD ± 164) which is substantially below the accepted teratogenic dose.CONCLUSIONS:ERCP in pregnancy seems to be safe for both mother and fetus; however, it should be restricted to therapeutic indications with additional intraprocedure safety measures.


The American Journal of Gastroenterology | 2000

Pancreatic duct stents for “obstructive type” pain in pancreatic malignancy

Tony C K Tham; David R. Lichtenstein; Jo Vandervoort; Richard C.K. Wong; A Slivka; Peter A. Banks; H B Yim; David L. Carr-Locke

Abstract OBJECTIVE: Obstruction of the main pancreatic duct from malignancy with secondary ductal hypertension may be an important contributor to pain. The aim of our study was to determine the efficacy and safety of pancreatic stent placement for patients with “obstructive” pain due to pancreatic malignancy. METHODS: Pancreatic duct stents were placed in 10 consecutive patients with malignant pancreatic duct obstruction and abdominal pain. Seven patients had “obstructive” type pain and three had chronic unremitting pain. Nine had primary pancreatic ductal adenocarcinoma and one had metastatic melanoma. There were eight women and two men. Mean age was 61 yr (range, 47–80 yr). All patients had dominant main pancreatic duct strictures with proximal dilation. Tumors were unresectable. All patients took potent analgesics before endoscopic stent therapy. Polyethylene pancreatic stents, 5- and 7-French, were successfully placed in seven patients, and self-expanding metallic stents were successfully placed in three patients. RESULTS: There were no procedure-related complications. One patient required a single repeat examination to replace a migrated stent. Seven patients (75%) experienced a reduction in pain. Analgesia was no longer required in five (50%). Three patients who did not improve had chronic pain rather than “obstructive” pain. CONCLUSIONS: Pancreatic stent placement for patients with “obstructive” pain secondary to a malignant pancreatic duct stricture appears to be safe and effective. It should be considered as a therapeutic option in these patients. It does not seem to be effective for chronic unremitting pain.


Pancreas | 1996

Urinary trypsinogen activation peptides (TAP) are not increased in mild ERCP-induced pancreatitis

Peter A. Banks; David L. Carr-Locke; Adam Slivka; J. Van Dam; David R. Lichtenstein; Michael D. Hughes

Acute pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP) occurs in 3–18% of patients undergoing either diagnostic or therapeutic ERCP. We prospectively measured urinary trypsinogen activation peptides (TAP) by an automated anti-TAP enzyme-linked immunoassay among 107 patients 4 h after ERCP to determine whether this measurement helps in the early diagnosis of ERCP-induced pancreatitis. Pan creatitis was documented in 10 of 107 patients (9.3%). All episodes were graded as mild. Urinary TAP was not significantly increased. We conclude that measurement of urinary TAP 4 h after ERCP is not helpful in documenting mild ERCP-induced acute pancreatitis.


International Journal of Pancreatology | 1995

Von Hippel-Lindau disease complicated by acute pancreatitis and Evan’s syndrome

Scott Tenner; Alfred Roston; David R. Lichtenstein; Gregory T. Sica; David L. Carr-Locke; Peter A. Banks

SummaryVon Hippel-Lindau syndrome (VHL) is an autosomal dominant disorder characterized by renal cysts, retinal angiomas, central nervous system hemangioblastomas, and pancreatic cysts. Evan’s syndrome is a hematologic disorder characterized by autoimmune thrombocytopenia and autoimmune hemolytic anemia. We present the first case of acute pancreatitis and Evan’s syndrome that developed in a patient with von Hippel-Lindau syndrome.


BMJ | 1996

Cost effectiveness of screening for and eradication of Helicobacter pylori in young patients with dyspepsia. Comparison groups were not clear in study.

Tony Tham; David R. Lichtenstein

EDITOR,—A H Briggs et al compared the cost effectiveness of screening for and eradication of Helicobacter pylori in the management of dyspeptic patients under 45 in the community using decision analysis and concluded that cost savings in the strategy of screening for H pylori compared with treatment with cimetidine could take almost eight years to accrue.1 We think, however, that there are flaws and limitations in this study and that their conclusions should be interpreted with caution.nnIn their analysis of …


Gastrointestinal Endoscopy | 2002

Pancreatic stent placement for duct disruption

Jennifer J. Telford; James J. Farrell; John R. Saltzman; Steven J. Shields; Peter A. Banks; David R. Lichtenstein; Richard S. Johannes; Peter B. Kelsey; David L. Carr-Locke


Arthritis & Rheumatism | 1995

Nonsteroidal antiinflammatory drugs and the gastrointestinal tract: The double-edged sword

David R. Lichtenstein; Sapna Syngal; M. Michael Wolfe


The American Journal of Gastroenterology | 1996

Intraductal mucin-hypersecreting neoplasm mucinous ductal ectasia : Endoscopic recognition and management

Scott Tenner; David L. Carr-Locke; Peter A. Banks; David C. Brooks; Van Dam J; Francis A. Farraye; Turner; David R. Lichtenstein

Collaboration


Dive into the David R. Lichtenstein's collaboration.

Top Co-Authors

Avatar

David L. Carr-Locke

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jo Vandervoort

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

A Slivka

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Henry Montes

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Richard C.K. Wong

Case Western Reserve University

View shared research outputs
Top Co-Authors

Avatar

Alfred Roston

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Roy Soetikno

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Frederick W. Ruymann

Brigham and Women's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge